HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Estee Lauder

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder: Prescriptives Lashes Natural, Lashes Intensified and Lashes Dramatic mascaras offer "three customized lash looks," the company's Prescriptives division said. The contoured Lashes Natural brush provide "consistent, even coverage," while Lashes Intensified's duo-zoned brush combs through each lash for lengthening benefits, the company said. The wide, spiraled Lashes Dramatic brush provides lashes with "maximum volume" and "ultimate thickness," Lauder added. Each mascara is formulated with laurel lysine for a smooth application, pantethine to repair and condition, and spherical beads for "superior thickening and lengthening benefits," the company said. Available now, each mascara is priced at $12.50...

You may also be interested in...



The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel